Timing of BNT162b2 vaccine prior to COVID‐19 infection, influence disease severity in patients with hematologic malignancies: Results from a cohort study
Abstract The COVID‐19 pandemic continues to pose challenges to the treatment of hemato‐oncology patients. Emergence of COVID‐19 variants, availability of vaccine boosters and antiviral treatments could impact their outcome. We retrospectively studied patients with hematologic malignancies and confir...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-11-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.6397 |
| _version_ | 1797542508089049088 |
|---|---|
| author | Odit Gutwein Katrin Herzog Tzarfati Arie Apel Naomi Rahimi‐Levene Levy Ilana Tamar Tadmor Maya Koren‐Michowitz |
| author_facet | Odit Gutwein Katrin Herzog Tzarfati Arie Apel Naomi Rahimi‐Levene Levy Ilana Tamar Tadmor Maya Koren‐Michowitz |
| author_sort | Odit Gutwein |
| collection | DOAJ |
| description | Abstract The COVID‐19 pandemic continues to pose challenges to the treatment of hemato‐oncology patients. Emergence of COVID‐19 variants, availability of vaccine boosters and antiviral treatments could impact their outcome. We retrospectively studied patients with hematologic malignancies and confirmed COVID‐19 during the Omicron outbreak. Of 116 evaluated patients, 16% developed severe or critical COVID‐19. Diagnosis of chronic lymphocytic leukemia (CLL) was significantly associated with severe COVID‐19 (p = 0.01). The vaccine effectiveness was related to the timing of the vaccine, with patients who received a mRNA vaccine within 7–90 days prior to COVID‐19 being less likely to develop severe disease compared to all other patients (p = 0.019). There was no correlation between disease severity and antiviral therapies. Importantly, 45% of patients undergoing active hematological treatment had to interrupt their treatment due to COVID‐19. In conclusion, patients with hematologic malignancies are at a considerable risk for severe COVID‐19 during the Omicron outbreak, with patients with CLL being the most vulnerable. mRNA vaccines have the potential to protect hematological patients from severe COVID‐19 if administered within the previous 3 months. Hematological treatment interruption is a frequent adverse outcome of COVID‐19 infection. |
| first_indexed | 2024-03-10T13:31:32Z |
| format | Article |
| id | doaj.art-fbafb69da3744f4397b68e13d8ef8e3c |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-03-10T13:31:32Z |
| publishDate | 2023-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-fbafb69da3744f4397b68e13d8ef8e3c2023-11-21T07:57:35ZengWileyCancer Medicine2045-76342023-11-011221205032051010.1002/cam4.6397Timing of BNT162b2 vaccine prior to COVID‐19 infection, influence disease severity in patients with hematologic malignancies: Results from a cohort studyOdit Gutwein0Katrin Herzog Tzarfati1Arie Apel2Naomi Rahimi‐Levene3Levy Ilana4Tamar Tadmor5Maya Koren‐Michowitz6Department of Hematology Shamir Medical Center (Assaf Harofeh) Zerifin IsraelDepartment of Hematology Shamir Medical Center (Assaf Harofeh) Zerifin IsraelDepartment of Hematology Shamir Medical Center (Assaf Harofeh) Zerifin IsraelDepartment of Hematology Shamir Medical Center (Assaf Harofeh) Zerifin IsraelHematology Unit Bnai Zion Medical Center Haifa IsraelHematology Unit Bnai Zion Medical Center Haifa IsraelDepartment of Hematology Shamir Medical Center (Assaf Harofeh) Zerifin IsraelAbstract The COVID‐19 pandemic continues to pose challenges to the treatment of hemato‐oncology patients. Emergence of COVID‐19 variants, availability of vaccine boosters and antiviral treatments could impact their outcome. We retrospectively studied patients with hematologic malignancies and confirmed COVID‐19 during the Omicron outbreak. Of 116 evaluated patients, 16% developed severe or critical COVID‐19. Diagnosis of chronic lymphocytic leukemia (CLL) was significantly associated with severe COVID‐19 (p = 0.01). The vaccine effectiveness was related to the timing of the vaccine, with patients who received a mRNA vaccine within 7–90 days prior to COVID‐19 being less likely to develop severe disease compared to all other patients (p = 0.019). There was no correlation between disease severity and antiviral therapies. Importantly, 45% of patients undergoing active hematological treatment had to interrupt their treatment due to COVID‐19. In conclusion, patients with hematologic malignancies are at a considerable risk for severe COVID‐19 during the Omicron outbreak, with patients with CLL being the most vulnerable. mRNA vaccines have the potential to protect hematological patients from severe COVID‐19 if administered within the previous 3 months. Hematological treatment interruption is a frequent adverse outcome of COVID‐19 infection.https://doi.org/10.1002/cam4.6397COVID‐19COVID‐19 vaccinehematologic malignanciesOmicron |
| spellingShingle | Odit Gutwein Katrin Herzog Tzarfati Arie Apel Naomi Rahimi‐Levene Levy Ilana Tamar Tadmor Maya Koren‐Michowitz Timing of BNT162b2 vaccine prior to COVID‐19 infection, influence disease severity in patients with hematologic malignancies: Results from a cohort study Cancer Medicine COVID‐19 COVID‐19 vaccine hematologic malignancies Omicron |
| title | Timing of BNT162b2 vaccine prior to COVID‐19 infection, influence disease severity in patients with hematologic malignancies: Results from a cohort study |
| title_full | Timing of BNT162b2 vaccine prior to COVID‐19 infection, influence disease severity in patients with hematologic malignancies: Results from a cohort study |
| title_fullStr | Timing of BNT162b2 vaccine prior to COVID‐19 infection, influence disease severity in patients with hematologic malignancies: Results from a cohort study |
| title_full_unstemmed | Timing of BNT162b2 vaccine prior to COVID‐19 infection, influence disease severity in patients with hematologic malignancies: Results from a cohort study |
| title_short | Timing of BNT162b2 vaccine prior to COVID‐19 infection, influence disease severity in patients with hematologic malignancies: Results from a cohort study |
| title_sort | timing of bnt162b2 vaccine prior to covid 19 infection influence disease severity in patients with hematologic malignancies results from a cohort study |
| topic | COVID‐19 COVID‐19 vaccine hematologic malignancies Omicron |
| url | https://doi.org/10.1002/cam4.6397 |
| work_keys_str_mv | AT oditgutwein timingofbnt162b2vaccinepriortocovid19infectioninfluencediseaseseverityinpatientswithhematologicmalignanciesresultsfromacohortstudy AT katrinherzogtzarfati timingofbnt162b2vaccinepriortocovid19infectioninfluencediseaseseverityinpatientswithhematologicmalignanciesresultsfromacohortstudy AT arieapel timingofbnt162b2vaccinepriortocovid19infectioninfluencediseaseseverityinpatientswithhematologicmalignanciesresultsfromacohortstudy AT naomirahimilevene timingofbnt162b2vaccinepriortocovid19infectioninfluencediseaseseverityinpatientswithhematologicmalignanciesresultsfromacohortstudy AT levyilana timingofbnt162b2vaccinepriortocovid19infectioninfluencediseaseseverityinpatientswithhematologicmalignanciesresultsfromacohortstudy AT tamartadmor timingofbnt162b2vaccinepriortocovid19infectioninfluencediseaseseverityinpatientswithhematologicmalignanciesresultsfromacohortstudy AT mayakorenmichowitz timingofbnt162b2vaccinepriortocovid19infectioninfluencediseaseseverityinpatientswithhematologicmalignanciesresultsfromacohortstudy |